Illumina has patented exocyclic amine-substituted coumarin derivatives as fluorescent labels for nucleotides in DNA sequencing. The method involves incorporating labeled nucleotides into growing DNA chains and detecting fluorescent signals for sequencing different template polynucleotides. GlobalData’s report on Illumina gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Illumina Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to GlobalData’s company profile on Illumina, Microfluidics automation was a key innovation area identified from patents. Illumina's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Fluorescent labels for nucleotides in dna sequencing

Source: United States Patent and Trademark Office (USPTO). Credit: Illumina Inc

A recently granted patent (Publication Number: US11884825B2) discloses a method for sequencing different template polynucleotides using a unique approach. The method involves incorporating various nucleotides with 3' blocking groups attached to a 2-deoxyribose sugar into growing polynucleotide chains that are complementary to the templates to be sequenced. These nucleotides are labeled with a specific compound, Formula (I), allowing for imaging and detection of fluorescent signals as they are incorporated. The process also includes removing the blocking groups from the nucleotides after incorporation, with the option to repeat the sequencing cycles multiple times. Additionally, the method can be performed on an automated sequencing instrument equipped with two light sources operating at different wavelengths, enhancing the efficiency of the sequencing process.

Furthermore, the patent also describes a method for preparing different growing polynucleotide chains complementary to specific template single-stranded polynucleotides. This method involves incorporating nucleotides with 3' blocking groups and removing these groups post-incorporation. Similar to the previous method, at least one nucleotide is labeled with the compound of Formula (I) for visualization and detection purposes. The template single-stranded polynucleotides can be immobilized on a solid support to facilitate the sequencing process. The patent outlines specific variations in the chemical structure of the labeled nucleotides, such as the presence of different functional groups and substitutions, to optimize the sequencing efficiency and accuracy. Overall, these methods offer innovative approaches to sequencing DNA that can potentially improve the speed and accuracy of genetic analysis in various applications.

To know more about GlobalData’s detailed insights on Illumina, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.